SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Puma Biotechnology, Inc. (PBYI) News

Follow Puma Biotechnology, Inc. (PBYI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol PBYI Asset equity Sector Markets 90 days 8 Last 7.045 Updated Nov 05, 2026, 09:57 PM UTC Open live news feed Open PBYI chart & news
M Puma Biotechnology Q3 Product Revenue Rises on NERLYNX Demand EQUITY | Nov 05, 2026, 09:57 PM UTC M Puma Biotechnology Q3 Net Income Falls to $6.0M Q3 2026 revenue was $55.1 million, up from $54.5 million a year earlier; GAAP net income fell to $6.0 million from $8.8 million. EARNINGS | Nov 05, 2026, 09:06 PM UTC M Puma Biotechnology Reports Third-Quarter 2026 Financial Results Puma Biotechnology announced results for the quarter ended September 30, 2026. The supplied report excerpt contains no financial figures. EQUITY | Nov 05, 2026, 09:05 PM UTC H Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript On Thursday, Puma Biotechnology (NASDAQ: PBYI ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data a LIVE | Oct 12, 2026, 09:18 AM UTC H PBYI: Revenue and clinical momentum accelerate, with biomarker-driven trials advancing in 2026 NERLYNX continues to drive revenue growth, with raised guidance for 2026 and strong U.S. and international sales. Alisertib's phase II trials in breast and lung cancer show promising efficacy, especially in biomarker-def EARNINGS | Sep 14, 2026, 08:39 PM UTC H PBYI: Strong revenue growth and promising clinical progress with biomarker-driven cancer therapies NERLYNX continues to show strong revenue growth and expanded guidance, while alisertib advances in phase II trials for breast and lung cancer with promising biomarker-driven results. Additional interim data and a focus o EARNINGS | Sep 14, 2026, 08:06 PM UTC L Puma Biotechnology to present at H.C. Wainwright 28th Annual Global Investment Conference Puma Biotechnology said Alan H. Auerbach will provide an overview of Puma at 3:30 p.m. ET on Monday, September 14, at the H.C. Wainwright 28th Annual Global Investment Conference. EQUITY | Sep 09, 2026, 08:11 PM UTC L Puma Biotechnology board panel approves inducement RSU awards Puma Biotechnology’s Compensation Committee approved inducement restricted stock unit awards covering 33,550 shares to five new non-executive employees, under Nasdaq Listing Rule 5635(c)(4), dated Sept. 1, 2026. EQUITY | Sep 03, 2026, 09:00 PM UTC L Puma Biotechnology Raises FY2026 Sales Guidance from $222.000M-$229.000M to $224.000M-$231.000M vs $222.000M Est Puma Biotechnology (NASDAQ: PBYI ) raises FY2026 sales outlook from $222.000 million-$229.000 million to $224.000 million-$231.000 million vs $222.000 million estimate. EARNINGS | Aug 06, 2026, 08:40 PM UTC